219 related articles for article (PubMed ID: 17700717)
1. Agonist potency at P2X7 receptors is modulated by structurally diverse lipids.
Michel AD; Fonfria E
Br J Pharmacol; 2007 Oct; 152(4):523-37. PubMed ID: 17700717
[TBL] [Abstract][Full Text] [Related]
2. Species and response dependent differences in the effects of MAPK inhibitors on P2X(7) receptor function.
Michel AD; Thompson KM; Simon J; Boyfield I; Fonfria E; Humphrey PP
Br J Pharmacol; 2006 Dec; 149(7):948-57. PubMed ID: 17031382
[TBL] [Abstract][Full Text] [Related]
3. Serum constituents can affect 2'-& 3'-O-(4-benzoylbenzoyl)-ATP potency at P2X(7) receptors.
Michel AD; Xing M; Humphrey PP
Br J Pharmacol; 2001 Apr; 132(7):1501-8. PubMed ID: 11264244
[TBL] [Abstract][Full Text] [Related]
4. Direct labelling of the human P2X7 receptor and identification of positive and negative cooperativity of binding.
Michel AD; Chambers LJ; Clay WC; Condreay JP; Walter DS; Chessell IP
Br J Pharmacol; 2007 May; 151(1):103-14. PubMed ID: 17339830
[TBL] [Abstract][Full Text] [Related]
5. [3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors.
Donnelly-Roberts DL; Namovic MT; Surber B; Vaidyanathan SX; Perez-Medrano A; Wang Y; Carroll WA; Jarvis MF
Neuropharmacology; 2009 Jan; 56(1):223-9. PubMed ID: 18602931
[TBL] [Abstract][Full Text] [Related]
6. Complexities of measuring antagonist potency at P2X(7) receptor orthologs.
Hibell AD; Thompson KM; Xing M; Humphrey PP; Michel AD
J Pharmacol Exp Ther; 2001 Mar; 296(3):947-57. PubMed ID: 11181928
[TBL] [Abstract][Full Text] [Related]
7. Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states.
Donnelly-Roberts DL; Jarvis MF
Br J Pharmacol; 2007 Jul; 151(5):571-9. PubMed ID: 17471177
[TBL] [Abstract][Full Text] [Related]
8. Negative and positive allosteric modulators of the P2X(7) receptor.
Michel AD; Chambers LJ; Walter DS
Br J Pharmacol; 2008 Feb; 153(4):737-50. PubMed ID: 18071294
[TBL] [Abstract][Full Text] [Related]
9. Extracellular ATP-induced calcium signaling in mIMCD-3 cells requires both P2X and P2Y purinoceptors.
Xia SL; Wang L; Cash MN; Teng X; Schwalbe RA; Wingo CS
Am J Physiol Renal Physiol; 2004 Aug; 287(2):F204-14. PubMed ID: 15068972
[TBL] [Abstract][Full Text] [Related]
10. Osteoblast responses to nucleotides increase during differentiation.
Orriss IR; Knight GE; Ranasinghe S; Burnstock G; Arnett TR
Bone; 2006 Aug; 39(2):300-9. PubMed ID: 16616882
[TBL] [Abstract][Full Text] [Related]
11. Characterization of ATP-gated P2X7 receptors in fish provides new insights into the mechanism of release of the leaderless cytokine interleukin-1 beta.
López-Castejón G; Young MT; Meseguer J; Surprenant A; Mulero V
Mol Immunol; 2007 Feb; 44(6):1286-99. PubMed ID: 16837047
[TBL] [Abstract][Full Text] [Related]
12. Apparent species differences in the kinetic properties of P2X(7) receptors.
Hibell AD; Kidd EJ; Chessell IP; Humphrey PP; Michel AD
Br J Pharmacol; 2000 May; 130(1):167-73. PubMed ID: 10781013
[TBL] [Abstract][Full Text] [Related]
13. A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat.
Honore P; Donnelly-Roberts D; Namovic MT; Hsieh G; Zhu CZ; Mikusa JP; Hernandez G; Zhong C; Gauvin DM; Chandran P; Harris R; Medrano AP; Carroll W; Marsh K; Sullivan JP; Faltynek CR; Jarvis MF
J Pharmacol Exp Ther; 2006 Dec; 319(3):1376-85. PubMed ID: 16982702
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of action of species-selective P2X(7) receptor antagonists.
Michel AD; Ng SW; Roman S; Clay WC; Dean DK; Walter DS
Br J Pharmacol; 2009 Apr; 156(8):1312-25. PubMed ID: 19309360
[TBL] [Abstract][Full Text] [Related]
15. Identification of regions of the P2X(7) receptor that contribute to human and rat species differences in antagonist effects.
Michel AD; Clay WC; Ng SW; Roman S; Thompson K; Condreay JP; Hall M; Holbrook J; Livermore D; Senger S
Br J Pharmacol; 2008 Nov; 155(5):738-51. PubMed ID: 18660826
[TBL] [Abstract][Full Text] [Related]
16. [3H]A-317491, a novel high-affinity non-nucleotide antagonist that specifically labels human P2X2/3 and P2X3 receptors.
Jarvis MF; Bianchi B; Uchic JT; Cartmell J; Lee CH; Williams M; Faltynek C
J Pharmacol Exp Ther; 2004 Jul; 310(1):407-16. PubMed ID: 15024037
[TBL] [Abstract][Full Text] [Related]
17. P2X(7) receptors are redistributed on human monocytes after pore formation in response to prolonged agonist exposure.
Connon CJ; Young RD; Kidd EJ
Pharmacology; 2003 Mar; 67(3):163-8. PubMed ID: 12571413
[TBL] [Abstract][Full Text] [Related]
18. Two haplotypes of the P2X(7) receptor containing the Ala-348 to Thr polymorphism exhibit a gain-of-function effect and enhanced interleukin-1beta secretion.
Stokes L; Fuller SJ; Sluyter R; Skarratt KK; Gu BJ; Wiley JS
FASEB J; 2010 Aug; 24(8):2916-27. PubMed ID: 20360457
[TBL] [Abstract][Full Text] [Related]
19. Expression of a P2X7 receptor by a subpopulation of human osteoblasts.
Gartland A; Hipskind RA; Gallagher JA; Bowler WB
J Bone Miner Res; 2001 May; 16(5):846-56. PubMed ID: 11341329
[TBL] [Abstract][Full Text] [Related]
20. ATP, a partial agonist for the P2Z receptor of human lymphocytes.
Gargett CE; Cornish JE; Wiley JS
Br J Pharmacol; 1997 Nov; 122(5):911-7. PubMed ID: 9384508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
